LBA4 Updated overall survival (OS) results from the first-line (1L) population in the phase III MONALEESA-3 trial of postmenopausal patients (PTS) with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib (RIB) + fulvestrant (FUL)

Subjects

Subjects :

Oncology
Hematology

Details

ISSN :

09237534

Volume :

33

Database :

OpenAIRE

Journal :

Annals of Oncology

Accession number :

edsair.doi...........8782131bc8ee7cfe6cb6c0f3f4269dd9

Full Text :

https://doi.org/10.1016/j.annonc.2022.03.280